Check-Cap (NASDAQ:CHEK) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Up 18.1 %

NASDAQ CHEK opened at $0.79 on Friday. The stock has a market cap of $4.62 million, a price-to-earnings ratio of -0.26 and a beta of 0.20. Check-Cap has a fifty-two week low of $0.56 and a fifty-two week high of $3.04. The business has a fifty day moving average of $0.76 and a 200-day moving average of $0.97.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.